
The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1, a genetic disorder that causes noncancerous tumors to grow on nerves throughout the body.

PwC report identifies transformative trends impacting the pharma market this year and into the future.

The latest news for pharma industry insiders.

Many people are still uninformed about both the short- and long-term impacts of the virus.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited treatment options.

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

The latest news for pharma industry insiders.

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson disease.

Legos will take over from Roger Dansey, who will begin transitioning to retirement.

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with previously untreated diffuse large B-cell lymphoma.

Susan Cantrell responds to the tariffs on China, Canada, and Mexico.

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for refractory systemic lupus erythematosus with extrarenal involvement, marking the second such designation in autoimmune diseases.

Hiroyuki Okuzawa will step into the role starting in April.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients with HR–positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with Enhertu.

President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.

Dr. Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, discusses future plans for R&D Cloud.

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Senators Durbin and Grassley proposed the new regulations for direct-to-consumer pharma advertising.

The latest news for pharma industry insiders.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in vaccine rates.

Dr. Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought to market last year.